Preclinical antitumor activity of oral silibinin-meglumine in combination with erlotinib or gefitinib in the treatment of erlotinib-and gefitinib-resistant EGFR-mutant NSCLC mouse xenografts Conference Poster 2013 uri icon

publication date

  • 2013